Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham

Key Points

• Artiva is prioritizing rheumatoid arthritis (RA) as the lead indication for its off-the-shelf NK cell platform and expects an H1 efficacy data readout in at least 15 RA patients (most with ≥6 months follow-up) alongside updates on potential pivotal-trial discussions with the FDA.
• The therapy uses non‑genetically modified NK cells plus rituximab to drive deep B‑cell depletion and the company is targeting ~50% ACR50 in late-line RA; early autoimmunity data (32 patients) showed no CRS or ICANS and primarily transient cytopenias as the main safety signals.
• Artiva says one cord unit can yield ~4 trillion NK cells (enough for ~500–1,000 patients) and its 9,000 sq ft facility could treat a similar scale, and the company reported $108 million in cash with runway into Q2 2027.

Artiva Biotherapeutics NASDAQ: ARTV is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said during a discussion at the Needham Healthcare Conference. Speaking with Needham Senior Biotech Analyst Gil Blum, CEO Fred Aslan outlined the company’s mechanism of action, the upcoming clinical data catalyst in RA, and Artiva’s view of how safety, durability, and manufacturing scalability could shape adoption in community rheumatology settings.

Company background and RA focus

Aslan said Artiva was founded in 2019 based on technology originally developed over roughly a decade by GC Cell, a Korean company, to “massively scale NK cells.” Artiva’s lead asset is a non-genetically modified NK cell product used in combination with a monoclonal antibody, with the company now prioritizing RA as its lead indication.

He said the RA strategy is driven by the potential to deliver deep B-cell depletion with a regimen that is “quite tolerable to be used in a community setting” and scalable enough to reach “thousands of people” at a more accessible cost of goods. Artiva expects an “important potential inflection” in the first half of the year, when it plans to share clinical efficacy data in RA in at least 15 patients—most with six months or more of follow-up—and provide an update on interactions with the U.S. Food and Drug Administration regarding a potential pivotal trial.

Mechanism: NK cells plus rituximab to drive deep B-cell depletion

Aslan emphasized that Artiva’s approach does not genetically engineer its NK cells. Instead, the company uses a monoclonal antibody for targeting—specifically rituximab. He described the regimen as rituximab binding to B cells, activating the NK cells, which then kill B cells.

Drawing on oncology experience, Aslan said the company observed deep B-cell depletion with rituximab plus its NK cells, and reported outcomes “in line with auto CAR T” in terms of complete response rates and durability in aggressive non-Hodgkin lymphoma. He added that some patients treated more than two years ago remained in remission, and the company saw similar response and durability patterns when combining its NK cells with a CD30-targeted biologic in Hodgkin’s lymphoma.

Based on that depth of B-cell depletion, he said Artiva believes it may be able to drive a “reset” and durable clinical responses in autoimmune disease.

Upcoming RA data: efficacy expectations and durability goals

In discussing efficacy benchmarks, Aslan said ACR50 is typically evaluated at six months and is a regulatory “gold standard” measure. He framed the company’s target in the context of later-line RA patients, noting that ACR50 rates are higher earlier in treatment and can fall to “10%-20%” in patients who have failed two distinct targeted mechanisms. Artiva, he said, is “driving towards” having 50% of patients achieve an ACR50 response in a late-line setting.

He also argued that unmet need persists in RA despite the number of approved drugs, saying registrational trials have generally focused on biologic-naïve patients or those who failed only one targeted therapy. He said about 25% of patients who start a biologic or JAK inhibitor ultimately have an inadequate response to two distinct mechanisms.

On study status, Aslan said Artiva previously reported treating 32 autoimmunity patients as of an Oct. 1 cutoff disclosed in an October-November update, and said enrollment has continued. For the planned RA efficacy update, he reiterated guidance of at least 15 RA patients, with most having six months or more follow-up, and said one or two patients would have longer follow-up given the first RA patient was treated roughly 12 to 18 months ago.

Looking beyond the near-term readout, Aslan said a median duration of response of at least 18 months would be “very compelling” in refractory RA patients, particularly because patients could potentially be off other immunomodulatory drugs during response. He cautioned that establishing long-term durability will take time, saying the company would need longer follow-up to understand durability fully.

Safety and community setting administration

Aslan highlighted differences from CAR T approaches, stating the company has seen “no CRS” and “no ICANS” in the first 32 autoimmunity patients presented in November, and did not see a need for tocilizumab for cytokine release syndrome. He also said the company observed no IVIG use for hypogammaglobulinemia in that dataset.

He characterized side effects as those associated with cyclophosphamide, fludarabine, and rituximab, noting that cyclophosphamide and fludarabine cause transient cytopenias generally lasting two to three weeks, during which patients receive prophylactic anti-infectives. In the November dataset, he said there was “basically only one patient” who required hospitalization due to an ear infection and abscess that required drainage and a short course of IV antibiotics.

Aslan also addressed physician concerns around lymphodepletion, saying rheumatologists may react differently when the risk-benefit discussion is framed around higher response rates and potential durability. He said more than 95% of treated patients have been managed in community rheumatology practices where physicians administer cyclophosphamide, fludarabine, rituximab, and the cells, and monitor patients. He said initial hesitation around fludarabine tends to subside after clinicians gain experience, with feedback that the regimen is “quite easy to use.”

Manufacturing scale and financial runway

On manufacturing, Aslan said Artiva sources NK cells from umbilical cord units and can generate “four trillion cells” from a single cord unit—an amount he said could treat approximately 500 to 1,000 patients. He attributed scalability in part to the absence of genetic engineering and described the process as similar to biologics manufacturing, involving expansion and bioreactor growth.

He also said Artiva has a 9,000 square foot facility that, “at capacity,” could treat 500 to 1,000 patients, and argued the investments required to scale production could be “a lot closer to a biologic than one would expect” given the maturity of the process.

In closing remarks, Aslan said Artiva ended 2025 with $108 million in cash and has guided that it has sufficient runway into the second quarter of 2027. He also urged investors to focus less on platform comparisons and more on questions of unmet need, time to market, target product profile, and real-world adoption—an approach Blum summarized as focusing on “actual drugs in patients.”

About Artiva Biotherapeutics NASDAQ: ARTV

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.